| 產(chǎn)品名稱 |
DMS 53 |
| 商品貨號 |
B164362 |
| Organism |
Homo sapiens, human |
| Tissue |
lung |
| Product Format |
frozen |
| Morphology |
epithelial |
| Culture Properties |
adherent |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
carcinoma; small cell lung cancer |
| Age |
54 years |
| Gender |
male |
| Ethnicity |
Caucasian |
| Storage Conditions |
liquid nitrogen vapor phase |
| Derivation |
The line was established from cells from a mediastinal biopsy of a patient with small cell carcinoma of the lung.
The patient had not received prior therapy. |
| Clinical Data |
54 years
Caucasian
male |
| Antigen Expression |
Leu 7; My23 |
| Receptor Expression |
bombesin, expressed epidermal growth factor (EGF), expressed transforming growth factor beta (TGF beta), expressed acetylcholine, expressed |
| Genes Expressed |
adrenocorticotropin (adrenocorticotropic hormone, ACTH); bombesin; calcitonin; human chorionic gonadotropin (hCG); glucagon; growth hormone; 17 beta estradiol; thyroid releasing hormone; oxytocin - neurophysin (OT-NP); parathormone;,somatostatin-like immunoreactivity (SRIF) |
| Cellular Products |
adrenocorticotropin (adrenocorticotropic hormone, ACTH); bombesin; calcitonin; human chorionic gonadotropin (hCG); glucagon; growth hormone; 17 beta estradiol; thyroid releasing hormone; oxytocin - neurophysin (OT-NP); parathormone; somatostatin-like immunoreactivity (SRIF) |
| Tumorigenic |
Yes |
| Effects |
Yes, tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 107 cells. |
| Comments |
The patient had not received prior therapy.
The cells express HLA class I and class II antigens.
Early passages of the cells were contaminated with a bovine mycoplasma (Acholeplasma laidlawii) which was cured (prior to cryopreservation) with A. laidlawii antiserum and kanamycin derived products.
|
| Complete Growth Medium |
Waymouth's MB 752/1 medium, 90%; fetal bovine serum, 10%
|
| Subculturing |
Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
- Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C.
Subcultivation Ratio: 1:2 to 1:3
Medium Renewal: Every 2 to 3 days
Note: Keep cells heavy and subculture often. |
| Cryopreservation |
Freeze Medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage Temperature: Liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: Air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile |
Amelogenin: X CSF1PO: 12 D13S317: 10 D16S539: 12,13 D5S818: 10,11 D7S820: 8,11 THO1: 8,9.3 TPOX: 12 vWA: 15,17 |
| Name of Depositor |
OS Pettengill, G Sorenson |
| Deposited As |
Homo sapiens |
| Passage History |
Early passages of the cells were contaminated with a bovine mycoplasma (Acholeplasma laidlawii) which was cured (prior to cryopreservation) with A. laidlawii antiserum and kanamycin derived products. |
| Year of Origin |
1974 |
| References |
Pettengill OS, et al. Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung. Cancer 45: 906-918, 1980. PubMed: 6266631
Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760
|
